You're asking about a compound with a very long and complex chemical name. This compound, often referred to as **compound A** or **CAS 1125172-88-2**, is a **small molecule inhibitor** that has garnered significant interest in research.
**Here's what makes it important:**
* **Target:** Compound A is a **potent and selective inhibitor** of the **enzyme Histone Deacetylase 6 (HDAC6)**.
* **HDAC6's Role:** HDAC6 is a critical enzyme involved in various cellular processes, including:
* **Protein degradation:** HDAC6 helps regulate the breakdown of misfolded or damaged proteins.
* **Microtubule dynamics:** HDAC6 influences the stability and organization of microtubules, which are essential for cell structure and movement.
* **Inflammation:** HDAC6 can regulate inflammatory responses.
* **Therapeutic Potential:** Inhibition of HDAC6 has shown promise in treating a range of diseases, including:
* **Cancer:** Compound A has been shown to have anti-tumor activity in preclinical studies, potentially due to its ability to induce cell death in cancer cells.
* **Neurological disorders:** HDAC6 inhibition has been linked to neuroprotective effects in animal models of Alzheimer's disease and Parkinson's disease.
* **Inflammation:** HDAC6 inhibition could potentially reduce inflammation in conditions like arthritis and inflammatory bowel disease.
**Research significance:**
* **New Drug Development:** Compound A and similar HDAC6 inhibitors represent potential new drug candidates for treating various diseases. Researchers are exploring their efficacy and safety profiles in clinical trials.
* **Understanding HDAC6 Function:** Studying the effects of HDAC6 inhibitors like compound A provides valuable insights into the role of HDAC6 in cellular processes and disease development.
**Note:** While compound A shows promise, it is still under investigation, and further research is needed to determine its long-term safety and efficacy in humans.
| ID Source | ID |
|---|---|
| PubMed CID | 2090539 |
| CHEMBL ID | 1530671 |
| CHEBI ID | 116573 |
| Synonym |
|---|
| MLS000058105 , |
| smr000067536 |
| MLS000863825 |
| CHEBI:116573 |
| 1-[4-(4-chlorophenyl)sulfonylpiperazin-1-yl]-2-[(5,7-dimethyl-[1,2,4]triazolo[4,3-a]pyrimidin-3-yl)sulfanyl]ethanone |
| HMS2319C18 |
| 1-[4-(4-chlorophenyl)sulfonylpiperazino]-2-[(5,7-dimethyl-[1,2,4]triazolo[4,3-a]pyrimidin-3-yl)thio]ethanone |
| bdbm35372 |
| cid_2090539 |
| 1-[4-(4-chlorophenyl)sulfonyl-1-piperazinyl]-2-[(5,7-dimethyl-[1,2,4]triazolo[4,3-a]pyrimidin-3-yl)thio]ethanone |
| CHEMBL1530671 |
| Q27199461 |
| Z21477639 |
| cid 2090539 |
| AKOS033772442 |
| Class | Description |
|---|---|
| sulfonamide | An amide of a sulfonic acid RS(=O)2NR'2. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 39.8107 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 35.4813 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 19.9526 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 10.0000 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
| P53 | Homo sapiens (human) | Potency | 79.4328 | 0.0731 | 9.6858 | 31.6228 | AID504706 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 0.7943 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 26.6250 | 0.0366 | 19.6376 | 50.1187 | AID1466; AID2112; AID2242 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 125.8920 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
| snurportin-1 | Homo sapiens (human) | Potency | 125.8920 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
| Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 35.4813 | 3.5481 | 18.0395 | 35.4813 | AID1466 |
| Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 35.4813 | 3.5481 | 18.0395 | 35.4813 | AID1466 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||